Cryptogenic stroke survivors who went on to get an insertable cardiac monitor (ICM) had a similar risk of recurrent stroke whether or not any atrial fibrillation (Afib, AF) ever turned up on ...

For patients with non-valvular atrial fibrillation (AFib) who had no contraindications to taking oral anticoagulants, the use of a device to close off the left atrial appendage in the heart—a small ...

Please provide your email address to receive an email when new articles are posted on . Asundexian did not prevent stroke or systemic embolism vs. apixaban in patients with atrial fibrillation despite ...

Please provide your email address to receive an email when new articles are posted on . In patients with embolic stroke of undetermined source, atrial fibrosis predicted recurrent stroke or new atrial ...

During atrial fibrillation, the heart's two small upper chambers tremble rather than beat, raising the risk of blood clots and stroke. Since the 1950s, AFib patients have relied on the anticoagulant ...

Researchers have developed a new way of identifying patients at risk of an irregular heartbeat, known as 'atrial fibrillation'. While not life threatening, the condition increases people's risk of ...

Boston Scientific (NYSE:BSX) executives highlighted new data from two randomized clinical trials during an American College of Cardiology conference call, describing the results as potentially ...

The idea of implanting a device inside the heart to block blood flow may sound counterintuitive, but in the case of left atrial appendage closure devices like Boston Scientific’s Watchman FLX, that ...

A series of neutral trials on anticoagulation in embolic stroke of undetermined source (ESUS) has moved the needle scientifically but left physicians with questions about secondary prevention and the ...

RARITAN, NJ, Janssen Pharmaceuticals, Inc. announced today the U.S. Food and Drug Administration (FDA) has approved XARELTO® to reduce the risk of stroke and systemic embolism in patients with ...